Pacira BioSciences Inc (NAS:PCRX)
$ 16.81 -0.7 (-4%) Market Cap: 776.17 Mil Enterprise Value: 998.18 Mil PE Ratio: 0 PB Ratio: 1.03 GF Score: 72/100

Pacira Biosciences Inc at Bank of America Merrill Lynch Health Care Conference Transcript

May 14, 2019 / 10:00PM GMT
Release Date Price: $46.59 (-0.66%)
Tazeen Ahmad
BofA Merrill Lynch, Research Division - VP

Good afternoon. Thanks for joining us. I'm Tazeen Ahmad. I'm the senior biotech analyst here at Bank of America Merrill Lynch. It's my pleasure to introduce our next presenting company, Pacira BioSciences. Sitting next to me is CEO, Dave Stack; and sitting next to him is CFO, Charlie Reinhart. Thanks, guys, for joining us.

David M. Stack
Pacira BioSciences, Inc. - Chairman & CEO

Thank you.

Tazeen Ahmad
BofA Merrill Lynch, Research Division - VP

So the format today is going to be Q&A, but I think for the benefit of everyone in the audience, maybe, Dave, you can give us a 2-minute introduction to Pacira and tell us what's been going on with the company, and then we can go from there.

David M. Stack
Pacira BioSciences, Inc. - Chairman & CEO

Sure. It's -- well, we're off to a good start. I mean things are good at Pacira. I think the best visibility, I think, I can give to anybody that's listening is the

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot